317-622-8970 Back to results

Array Biopharma Inc.

Boulder, Colorado

Boulder, Colorado, United States120 employees$250.0M revenue
Visit Website

Find prospects like Array Biopharma Inc.

Get a list of similar companies, matched by industry, size and location, ready for outreach.

Free sample of 25 companies by email within one business day. No spam: we only use your email for this request.

Products & Services

biotechnologylife sciencessmall molecule drug discovery & developmentoncologymelanomacolorectal cancer

About Array Biopharma Inc.

Array BioPharma Inc (Array) focuses on the discovery, development and commercialization of targeted small-molecule drugs. Its products are evaluated for the treatment of cancer, inflammation and pain. It operates through a single reportable business segment. The company's proprietary programs include binimetinib, a MEK inhibitor for cancer which completed Phase III trials for the treatment of cancer; encorafenib, a BRAF inhibitor in Phase III trials for cancer; Danoprevir, an NS3 Protease in Phase III clinical trials for the treatment of Hepatitis C. Other Phase II candidates include ARRY-797, a selective, oral inhibitor that acts on p38 mitogen activated protein kinase for the treatment of LMNA-DCM; ARRY-502, an oral, potent and highly selective CRTh2 antagonist under development to treat Th2-driven allergic diseases such as asthma. Candidates in Phase I include ARRY-382 for the treatment of cancer; ARRY-614, indicated for the treatment of myelodysplastic syndromes (MDS). The company seeks a prospective partner to develop this product further. ARRY-614 is a potent, a small molecule dual p38/Tie2 inhibitor, is being evaluated for the treatment of myelodysplastic syndromes. Array has out-licensing and collaboration agreements with several pharmaceutical companies for the development of its product candidates. Array has a license agreement with AstraZeneca for the development of selumetinib, a small molecule MEK inhibitor. MEK is a critical protein which indicates cancer cell conception and survival. Selumentinib is in Phase III clinical trials and is being evaluated for the treatment of advanced cancer conditions including KRAS-mutant advanced or metastatic non small lung cancer, metastatic uveal melanoma and differentiated thyroid cancer. The company and InterMune jointly discovered danoprevir, a small molecule inhibitor of hepatitis C virus. Later, Roche purchased danoprevir for a cash consideration of US$175 million. The company receives milestone payments based on the selection and progress of danoprevir from Intermune. It also receives royalties on commercial sales of this product. The company has an agreement with Aslan Pharmaceuticals for the development of ARRY-543, an oral HER2 / EGFR inhibitor evaluated against HER2-positive and EGFR-positive tumors. The product is currently evaluated in Phase II development in patients with gastric or breast cancer in Asia. Array reached a drug discovery collaboration agreement with Genentech to develop small molecule drugs against multiple targets in cancer. The company initiated three programs, namely, Ipatasertib/GDC-0068, in Phase II trials; and GDC-0994 and GDC-0575, Phase I development stage candidates. LY2606368 is a small molecule ChK-1 inhibitor developed under an agreement with Eli Lilly. The company evaluated this product against cancer indications. It is in Phase II clinical trials. Array has a collaboration and license agreement with VentiRx, under which the company granted VentiRx worldwide rights to certain molecules from its TLR program. The program comprises many compounds including VTX-2337, a toll like receptor indicated for cancer. These compounds activate innate immunity by targeting TLRs. VTX-2337 is in Phase II clinical trials. The company reached a development and commercialization agreement with Cascadian Therapeutics to collaboratively develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor under developed for the treatment of cancer, including breast cancer. Under the terms of agreement, Cascadian Therapeutics undertakes the clinical development of ARRY-380 through proof of concept trials in patients with metastatic breast cancer. Array and Cascadian Therapeutics will be responsible for 50% development costs each with respect to Phase III development. Array undertakes the activities related to the commercialization of this product worldwide. Cascadian Therapeutics is responsible for 50% of the co-promotion activities in the US. Array entered into a drug discovery collaboration agreement with Loxo to develop and commercialize some of the company’s compounds targeted at the Trk receptors, including LOXO-101. The product is in Phase I clinical trials. Some of the major revenue contributors of the company in year ended June 30, 2017 (FY2017) include Novartis which accounted for 70.3% of the company’s total revenue; followed by Loxo Oncology with 10.8%; and Cascadian Therapeutics (formerly Oncothyreon Inc.), with 0.1%. In FY2017 Array’s license and milestone revenue amounted to US$19.84 million, which accounted for 13.2% of the company’s total revenue; reimbursement revenue amounting to US$107.19 million accounted for 71.8% and collaboration revenue amounted to US$23.8 million, which accounted for 15.8% of the company’s total revenue. Geographically, the company classifies its revenue into three regions, namely, North America, Europe and Asia Pacific. In FY2017, the North American region accounted for 81.5% of the company's total revenue; followed by Europe with 14.7% and Asia Pacific accounted for 2.5% of the company's total revenue.

Array Biopharma Inc. is one of 1,051,696 companies listed in Colorado.

Business Contact Information

Phone
+1 (303) 3816600
Address
3200 Walnut St, Boulder, Colorado, 80301, United States

Company Details

Employees
120
Annual Revenue
$250.0M

Array Biopharma Inc.: frequently asked questions

What does Array Biopharma Inc. do?

Array BioPharma Inc (Array) focuses on the discovery, development and commercialization of targeted small-molecule drugs. Its products are evaluated for the treatment of cancer, inflammation and pain. It operates through a single reportable business segment.

Where is Array Biopharma Inc. located?

Array Biopharma Inc. is located at 3200 Walnut St, Boulder, Colorado, 80301, United States.

How many employees does Array Biopharma Inc. have?

Array Biopharma Inc. has about 120 employees.

What is Array Biopharma Inc.'s annual revenue?

Array Biopharma Inc.'s annual revenue is estimated at $250.0M.

How can I contact Array Biopharma Inc.?

Its website is www.arraybiopharma.com and its phone number is +1 (303) 3816600.

Largest companies on Factur

Own this business?

Keep your profile accurate — or ask us to take it down. We acknowledge requests within 7 days and resolve them within 30 days.

Prefer email? privacy@facturmfg.com

Add this badge to your website — show visitors you're listed on Factur Data.